Archive for the ‘Bone Marrow Stem Cells’ Category

Stem Cell Therapy - How Stem Cells Helped Emery with Pain and more!
Bone marrow stem cells helped Emery M. after having pain in his foot and other minor problems. He came to Dr. David Steenblock for adult stem cell treatments and did wonderfully. To find out more about bone marrow stem cells and how legal stem cells are done here in the US call Dr. Steenblock #39;s office: 1-800-300-1063.From:STEMCELLinfoViews:37 0ratingsTime:02:00More inScience Technology

Excerpt from:
Stem Cell Therapy - How Stem Cells Helped Emery with Pain and more! - Video

Stem cells for critical limb ischemia (NAPLES Study).m4v
This is the procedure of intra arterial autologous transplant of bone marrow stem cells for the treatment of critical limb ischemia according to NAPLES Study.From:Alessandro SchiavettaViews:47 0ratingsTime:01:16More inScience Technology

See the original post here:
Stem cells for critical limb ischemia (NAPLES Study).m4v - Video

Stem Cell Therapy And Tissue Engineering For Cardiovascular Repair
xxsurl.com Stem Cell Therapy And Tissue Engineering For Cardiovascular Repair Ventricular Remodeling in Ischemic Cardiomyopathy.- Myocardial Regeneration: Which Cell and Why.- Cardiac Stem Cells for Myocardial Regeneration.- A Historic Recapitulation of Myoblast Transplantation.- Myoblast Cell Transplantation Preclinical Studies.- Skeletal Myoblasts: The European Experience.- Skeletal Myoblasts: The US Experience.- Progenitor Cells for Cardiac Regeneration.- Bone Marrow Derived Stem Cell for Myocardial Regeneration: Preclinical Experience.- Bone Marrow Derived Stem Cell for Myocardial Regeneration: Clinical Experience, Surgical Delivery.- Autologous Mononuclear Bone Marrow Cell Transplantation for Myocardial Infarction: The German Experience.- Autologous Mononuclear Bone Marrow Cell Transplantation for Myocardial Infarction: The Spanish Experience.- Mobilizing Bone Marrow Stem Cells for Myocardial Repair after Acute Myocardial Infarction.- Percutaneous Myoblast Transplantation: Steps in Translational Research.- A Porcine Model of Myocardial Infarction for Evaluation of Cell Transplantation.- Tissue Engineering for Myocardial Regeneration.- The Role of PET Scan in Stem Cell Therapy.- The Measurement of Systolic Function in the Mammalian Heart.- Electrophysiological Aspects of Cell Transplantation.- Regulatory Considerations in Manufacturing, Product Testing, and Preclinical Development of Cellular Products for Cardiac Repair.- Appendix: Catheter Descriptions.- Index. EAN ...From:maurinecooper3Views:56 0ratingsTime:00:12More inPeople Blogs

Link:
Stem Cell Therapy And Tissue Engineering For Cardiovascular Repair - Video

Own Bone Marrow Adult Stem Cells Renewed Heart Attack Patient
Proactive Stem cell options to renew hearts with own bone marrow stem cells .. http://www.EJMorris.biz Your own bone marrow stem cells help repair aging and damaged hearts and other organs. Many stem cell procedures are performed in India, and other international countries. Some adult stem cell releasing.. extracting .. and stem cell injection procedures are performed in the USA. Investigate all your stem cell nutrition options.. including Naturally Releasing MILLIONS more Stem Cells from your Bone Marrow within 60 MINUTES of consuming 2 patented adult stem cell nutrition capsules. Investigate a proactive wellness lifestyle by releasing MILLIONS more of YOUR OWN adult stem cells from your bone marrow EVERY DAY with adult stem cell nutrition capsules. Your body is indeed a Miracle.. and your own adult stem cells constitute Your body #39;s own RENEWAL SYSTEM to help in anti-aging and rejuvenation of not only your heart .. but ALL your organs, tissues and muscles. See VIDEO of patented stem cell nutrition including capsules, tablets granules,powders and serums.. httpFrom:EJ MorrisViews:43 0ratingsTime:04:17More inScience Technology

Read the rest here:
Own Bone Marrow Adult Stem Cells Renewed Heart Attack Patient - Video

Releasing Her Own Adult Stem Cells Renewed Lisa Ray
Stem cell options for releasing more bone marrow stem cells .. http://www.EJMorris.biz Lisa Ray #39;s own bone marrow stem cells helped repair her body. Some stem cell procedures are performed in India, and some adult stem cell releasing.. extracting .. and stem cell injection procedures are performed in the USA. Investigate all your stem cell nutrition options..including Naturally Releasing MILLIONS more Stem Cells from your Bone Marrow within 60 MINUTES of consuming 2 patented adult stem cell nutrition capsules. Investigate your body #39;s own RENEWAL SYSTEM, using your OWN Bone Marrow Adult Stem Cells for repair and rejuvenation.From:EJ MorrisViews:63 0ratingsTime:01:01More inScience Technology

Continued here:
Releasing Her Own Adult Stem Cells Renewed Lisa Ray - Video

Release Millions More Bone Marrow Stem Cells.. Your Body #39;s Renewal System
Witness Proactive Bone Marrow Stem Cell option Videos here.. http://www.EJMorris.biz See adult stem cell animation of renewing your body tissues and organs with your own bone marrow stem cells .. http Your own bone marrow stem cells help repair aging and damaged tissues, muscles, bones ,hearts and other organs. Many stem cell procedures are performed in India, and other international countries. Some adult stem cell releasing.. extracting .. and stem cell injection procedures are performed in the USA. Investigate all your stem cell nutrition options.. including Naturally Releasing 3 to 4 MILLION more Stem Cells from your Bone Marrow within 60 MINUTES of consuming 2 patented adult stem cell nutrition capsules. Investigate a proactive wellness lifestyle by releasing MILLIONS more of YOUR OWN adult stem cells from your bone marrow EVERY DAY with adult stem cell nutrition capsules. Your body is indeed a Miracle.. and your own adult stem cells constitute Your body #39;s own RENEWAL SYSTEM to help in anti-aging and rejuvenation of not only your heart .. but ALL your organs, tissues and muscles. See VIDEO of patented stem cell nutrition including capsules, tablets granules, powders and serums.. http://www.EJrecommends.comFrom:EJ MorrisViews:25 0ratingsTime:06:27More inScience Technology

More here:
Release Millions More Bone Marrow Stem Cells.. Your Body's Renewal System - Video

Stem Cell Doctors from India and Stem Cell Options
Review stem cell doctors and stem cell nutrition options from India ..www.EJrecommends.com .. then investigate how your own bone marrow stem cells help repair aging and damaged tissues, muscles, bones ,hearts and other organs. Many stem cell procedures are performed in India, and other international countries. Some adult stem cell releasing.. extracting .. and stem cell injection procedures are performed in the USA. Investigate all your stem cell nutrition options.. including Naturally Releasing 3 to 4 MILLION more Stem Cells from your Bone Marrow within 60 MINUTES of consuming 2 patented adult stem cell nutrition capsules. Investigate a proactive wellness lifestyle by releasing MILLIONS more of YOUR OWN adult stem cells from your bone marrow EVERY DAY with adult stem cell nutrition capsules. Your body is indeed a Miracle.. and your own adult stem cells constitute Your body #39;s own RENEWAL SYSTEM to help in anti-aging and rejuvenation of not only your heart .. but ALL your organs, tissues and muscles. See VIDEO of patented stem cell nutrition including capsules, tablets granules, powders and serums.. httpFrom:EJ MorrisViews:30 0ratingsTime:04:34More inScience Technology

View post:
Stem Cell Doctors from India and Stem Cell Options - Video

2012 Ask the Experts -3 Facts about Stem Cell Research - Dr Megan Munsie
Dr Megan Munsie, Stem Cells Australia spoke on Hope, Hype and Reality: The Facts about Stem Cell Research. Megan explained that headlines about stem cells are often sensational and oversimplify where research is at. Present use of cord blood and bone marrow stem cells is limited to diseases of the blood -- #39;like for like #39;. Over the last 20 years researchers have been able to identify stem cells in the kidney, heart and brain, but these cannot be effectively harnessed for treatments yet. There is often a great focus on the potential therapeutic use for stem cells, but where stem cells are currently making a great scientific contribution is as a research tool for finding out more information about the disease itself, for example we can now look at how MND develops using stem cells in a petri dish. There is currently a long list of stem cell treatment companies even though treatments are yet unproven. A person considering stem cell treatment should speak with their neurologist first to better understand the context of the proposed treatment because the neurologist will be more impartial than a company #39;selling #39; the treatment. Booklets are available through Stem Cells Australia at http://www.stemcellsaustralia.edu.au to help with right questions to ask.From:mndnswViews:33 0ratingsTime:33:25More inNonprofits Activism

Go here to read the rest:
2012 Ask the Experts -3 Facts about Stem Cell Research - Dr Megan Munsie - Video

Stem Cell Treatment Helps Shoulder Pain!
Kurt came to Dr. Steenblock for help with his shoulder. Kurt did bone marrow stem cells and had great results with helping heal his right shoulder heal. Find out more by calling Dr. Steenblock #39;s office today at 1-800-300-1063.From:STEMCELLinfoViews:49 0ratingsTime:01:40More inScience Technology

See the original post here:
Stem Cell Treatment Helps Shoulder Pain! - Video

Dog Arthritis helped with Dogs Own Adult Stem Cells
Arthritis in dogs can be helped with dogs OWN adult stem cells http://www.adult-stemcells-blog.com .. see stem cell nutrition options in tablets,capsules and granules, to release millions more of your dogs own bone marrow stem cells into his bloodstream to renew your sick dog with arthritis or other aging and health problems Witness another sick and aging dog being helped with his own stem cells and how to get more stem cells repairing Your sick dog WITHOUT Extractions.. and with NO Injections.. http://www.ejmorris.bizFrom:EJ MorrisViews:28 0ratingsTime:05:10More inPets Animals

View post:
Dog Arthritis helped with Dogs Own Adult Stem Cells - Video

Stem Cell : cervical vertebral stenotic myleopathy case - Blood stem cells
Atassia is a disease that affects the nervous system. In this specific case the horse was ten years old, and the diagnosis had been given when he was about a year old and over the years it had worsened as do most neurological pathologies. The fact that the horse improved by 70% over two months means that the stem cells that I use have the power to change themselves into nerve cells. This confirms " in vivo" that we have adult pluripotent stem cells, which, unlike fat and bone marrow stem cells, can change themselves into nervous tissue. We have some published papers that credit us with the discovery of pluripotent receptors in blood stem cells obtained "in vitro" with our patented system. In this first video the horse is totally uncoordinated and for months it had been impossible to ride him because the horse risked falling with the rider on top. You can see the notable rear muscle mass #39; atrophy.From:marcopolettiniengViews:34 1ratingsTime:04:55More inScience Technology

See the article here:
Stem Cell : cervical vertebral stenotic myleopathy case - Blood stem cells - Video

[RMS] Bone Marrow Stem Cell - OSSRON
Ossron is cultured autologous bone cells for bone formation. Ossron is performed by three stages : harvesting bone marrow from a patient #39;s own, cell culturing in stem cell processing center, and implanting the cultured bone cells into defect sites. Bone Marrow Stem Cell [BMSC] Bone marrow cells have shown an osteogenic potential. Only a small aspiration biopsy of bone marrow from the iliac crest is required to obtain these cells. Bone marrow stem cells are the most potent bone regenerator with abundant cell numbers, high viabilites, and highly expressed osteogenic activites. Bone marrow stem cells are able to generate tissue other than bone. These cells can be isolated, expanded in culture, and stimulated to differentiate into osteoblasts, adipocytes, chondrocytes, myocytes, neuronal cells and a variety of other connective tissue.From:SewonCellontechViews:1 0ratingsTime:06:24More inHowto Style

Read more:
[RMS] Bone Marrow Stem Cell - OSSRON - Video

ScienceDaily (Oct. 19, 2012) Claudio Anasetti, M.D., chair of the Department of Blood & Marrow Transplant at Moffitt Cancer Center, and colleagues from 47 research sites in the Blood and Marrow Transplant Clinical Trials Network conducted a two-year clinical trial comparing two-year survival probabilities for patients transplanted with peripheral blood stem cells or bone marrow stem cells from unrelated donors. The goal was to determine whether graft source, peripheral blood stem cells or bone marrow, affects outcomes in unrelated donor transplants for patients with leukemia or other hematologic malignancies.

Fifty transplant centers in the United States and Canada participated in this phase III study, which randomized 278 patients to receive bone marrow and 273 patients to receive peripheral blood stem cells as the graft source for transplant. The results of the study are in the Oct. 18 issue of The New England Journal of Medicine.

According to the trial analyses, there were no observed differences in overall survival, relapse, non-relapse mortality, or acute graft-versus-host disease (GHVD) between the patients receiving peripheral blood stem cells or bone marrow stem cells from unrelated donors. GVHD is a serious and often deadly post-transplant complication that occurs when the newly transplanted donor cells attack the transplant recipient's body. While engraftment was faster in patients receiving peripheral blood stem cells, there was a higher incidence of overall chronic GVHD in these patients (53 percent) than in those transplanted with bone marrow stem cells (40 percent). Patients receiving transplants of peripheral blood stem cells from unrelated donors also had a higher incidence of chronic GVHD affecting multiple organs (46 percent) than patients who received bone marrow stem cells (31 percent).

"Although peripheral blood stem cells from related donors have demonstrated clinical benefits, our trial demonstrates that when these stem cells originate from unrelated donors, they are not superior to bone marrow stem cells in terms of patient survival, and they increase the risk for chronic GVHD," said Anasetti, lead study author. "More effective strategies to prevent GVHD are needed to improve outcomes for all patients receiving unrelated donor transplants."

Peripheral blood stem cells are stem cells originally found in the bone marrow that have been moved into the blood stream by a special regimen of drugs. Unlike bone marrow stem cells, which must be extracted from the bones in an operating room, peripheral blood stem cells are more easily obtained through apheresis, a process similar to regular blood donation, which collects the peripheral blood stem cells through a tube inserted in a vein. A critical step before the transplant involves finding a donor that is tissue matched to the recipient.

About one-third of patients who need a peripheral blood stem cell or bone marrow transplant for treatment of leukemia or another blood disease are able to secure a related donor. According to the National Marrow Donor Program, for the 70 percent who cannot find a donor within their family, most will be able to find an unrelated donor. Because the majority of transplant patients need cells from unrelated donors, it's necessary to better understand the risks associated with transplants of unrelated donor cells.

Clinical trials on related donor transplants have demonstrated that peripheral blood stem cell transplants in patients with leukemia and other blood diseases result in better engraftment, lower relapse rates, and increased survival compared with transplants with bone marrow stem cells. However, those trials also found that peripheral blood stem cell transplants carry an increased risk of GVHD. Patients who survive early post-transplant may develop chronic GVHD, a disabling condition managed with long-term immunosuppressant therapy.

Many transplant centers are increasingly using peripheral blood stem cells as a source for adult stem cells because of their superiority in clinical trials that have directly compared outcomes between peripheral blood stem cells and bone marrow stem cells from related donors. However, there has not been a comparative study of the two transplant sources that has prospectively analyzed patient outcomes in unrelated donor transplants.

The study was funded by the National Heart, Lung and Blood Institute (U10HL069294), the National Cancer Institute and the National Marrow Donor Program.

Share this story on Facebook, Twitter, and Google:

Go here to read the rest:
No survival advantage with peripheral blood stem cells versus bone marrow, study suggests

Public release date: 19-Oct-2012 [ | E-mail | Share ]

Contact: Kim Polacek kim.polacek@moffitt.org 813-745-7408 H. Lee Moffitt Cancer Center & Research Institute

Claudio Anasetti, M.D., chair of the Department of Blood & Marrow Transplant at Moffitt Cancer Center, and colleagues from 47 research sites in the Blood and Marrow Transplant Clinical Trials Network conducted a two-year clinical trial comparing two-year survival probabilities for patients transplanted with peripheral blood stem cells or bone marrow stem cells from unrelated donors. The goal was to determine whether graft source, peripheral blood stem cells or bone marrow, affects outcomes in unrelated donor transplants for patients with leukemia or other hematologic malignancies.

Fifty transplant centers in the United States and Canada participated in this phase III study, which randomized 278 patients to receive bone marrow and 273 patients to receive peripheral blood stem cells as the graft source for transplant. The results of the study are in the Oct. 18 issue of The New England Journal of Medicine.

According to the trial analyses, there were no observed differences in overall survival, relapse, non-relapse mortality, or acute graft-versus-host disease (GHVD) between the patients receiving peripheral blood stem cells or bone marrow stem cells from unrelated donors. GVHD is a serious and often deadly post-transplant complication that occurs when the newly transplanted donor cells attack the transplant recipient's body. While engraftment was faster in patients receiving peripheral blood stem cells, there was a higher incidence of overall chronic GVHD in these patients (53 percent) than in those transplanted with bone marrow stem cells (40 percent). Patients receiving transplants of peripheral blood stem cells from unrelated donors also had a higher incidence of chronic GVHD affecting multiple organs (46 percent) than patients who received bone marrow stem cells (31 percent).

"Although peripheral blood stem cells from related donors have demonstrated clinical benefits, our trial demonstrates that when these stem cells originate from unrelated donors, they are not superior to bone marrow stem cells in terms of patient survival, and they increase the risk for chronic GVHD," said Anasetti, lead study author. "More effective strategies to prevent GVHD are needed to improve outcomes for all patients receiving unrelated donor transplants."

Peripheral blood stem cells are stem cells originally found in the bone marrow that have been moved into the blood stream by a special regimen of drugs. Unlike bone marrow stem cells, which must be extracted from the bones in an operating room, peripheral blood stem cells are more easily obtained through apheresis, a process similar to regular blood donation, which collects the peripheral blood stem cells through a tube inserted in a vein. A critical step before the transplant involves finding a donor that is tissue matched to the recipient.

About one-third of patients who need a peripheral blood stem cell or bone marrow transplant for treatment of leukemia or another blood disease are able to secure a related donor. According to the National Marrow Donor Program, for the 70 percent who cannot find a donor within their family, most will be able to find an unrelated donor. Because the majority of transplant patients need cells from unrelated donors, it's necessary to better understand the risks associated with transplants of unrelated donor cells.

Clinical trials on related donor transplants have demonstrated that peripheral blood stem cell transplants in patients with leukemia and other blood diseases result in better engraftment, lower relapse rates, and increased survival compared with transplants with bone marrow stem cells. However, those trials also found that peripheral blood stem cell transplants carry an increased risk of GVHD. Patients who survive early post-transplant may develop chronic GVHD, a disabling condition managed with long-term immunosuppressant therapy.

Many transplant centers are increasingly using peripheral blood stem cells as a source for adult stem cells because of their superiority in clinical trials that have directly compared outcomes between peripheral blood stem cells and bone marrow stem cells from related donors. However, there has not been a comparative study of the two transplant sources that has prospectively analyzed patient outcomes in unrelated donor transplants.

Read the original here:
Moffitt researcher says no survival advantage with peripheral blood stem cells versus bone marrow

ScienceDaily (Oct. 17, 2012) One of the world's leading bone marrow transplant experts is recommending a significant change to current transplant practice for patients who need marrow or adult stem cells from an unrelated donor to treat hematologic malignancies. Fred Appelbaum, M.D., director of the Clinical Research Division at Fred Hutchinson Cancer Research Center, asserts that bone marrow -- not circulating, peripheral blood, which is the current norm -- should be the source for unrelated donor adult stem cells for most patients who require a transplant. The reason: because there is less incidence of chronic graft-versus-host disease (GVHD), which can be a debilitating side effect of transplantation.

Appelbaum called for the change in an Oct. 18 editorial in The New England Journal of Medicine in response to a new study, published in the same issue, which compared survival rates and side effects of treating patients with hematopoietic adult stem cells derived from bone marrow versus circulating peripheral blood. The study found a higher incidence of chronic GVHD -- 53 percent when peripheral blood was the source of stem cells for transplant -- versus 41 percent when bone marrow is the source.

"For the majority of unrelated transplants following a standard high-dose preparative regimen, bone marrow should be used since survival is equivalent with the two sources but the incidence of chronic graft-versus-host disease, which can be a debilitating complication, is significantly less with marrow," Appelbaum wrote.

GVHD is a common side effect in people who receive cells from an unrelated donor. It occurs when the transplanted cells recognize the recipient's tissues as foreign and attack the tissues. This can cause a variety of problems, including skin rashes, liver problems and diarrhea. Chronic GVHD can develop any time between three months and three years after the transplant and can range from mild to serious in intensity.

Appelbaum said that stem cells derived from peripheral blood should only be used for the minority of patients in whom the benefits outweigh the risks. These include patients in need of rapid engraftment, such as those with life-threatening infections, or patients at high risk for graft rejection, such as those who receive reduced-intensity conditioning that does not include intensive chemotherapy.

For the past 10 years peripheral blood has been the norm as a source of matched related and matched unrelated adult stem cells for transplant because, despite the higher risk of GVHD, they are easier to harvest from the donor, they can be stimulated to grow in large numbers prior to harvesting, and they engraft, or set up shop, quickly inside the recipient's body.

The potential impact if such a practice change were widely implemented is large. Currently, about 75 percent of unrelated donor transplants are done using stem cells that are collected from the peripheral blood of donors. About 70 percent of all patients who undergo a life-saving transplant to treat blood cancers such as leukemia require an unrelated donor. Collecting adult stem cells from bone marrow is a more invasive process than collecting them from the bloodstream.

According to Appelbaum, about 5,500 unrelated donor transplants were performed in the United States last year. More than 20 million potential unrelated donors are typed and listed in registries in the Americas, Europe and Asia.

The study that compared the two sources of adult stem cells was the first randomized trial of its kind to compare the two sources of cells. It was led by former Hutchinson Center transplant physician Claudio Anasetti, M.D., who is now at the H. Lee Moffitt Cancer Center in Tampa, Fla. It found no difference in two-year survival, faster engraftment and less graft failure, but a significant increase in chronic GVHD, when patients were transplanted with stem cells derived from peripheral blood.

"While this study should change practice, it will be interesting to see if it really does," Appelbaum wrote. "The benefits of peripheral blood are seen early, under the watchful eyes of the transplant physician, while the deleterious effects occur late, often after the patient has left the transplant center."

Originally posted here:
Leading bone marrow transplant expert recommends significant change to current practice

Washington, October 17 (ANI): Researchers believe they have discovered stem cells that play a decisive role in new blood vessel growth.

If the researchers at the University of Helsinki, Finland, learn to isolate and efficiently produce these stem cells found in blood vessel walls, the cells offer new opportunities in the treatment of cardiovascular diseases, cancer and many other diseases.

The growth of new blood vessels, also known as angiogenesis, is needed in adults when repairing damaged tissue or organs.

Unfortunately, malignant tumours are also capable of growing new blood vessels to receive oxygen and nutrients. In other words, the treatment of diseases would benefit from two types of methods - ones that help launch the process of angiogenesis and ones that make it possible to prevent the process.

Medications that prevent the growth of new blood vessels have already been introduced, but their effectiveness and long-term efficacy leave much to be desired.

For more than a decade, Adjunct Professor Petri Salven from the University of Helsinki has studied the mechanisms of angiogenesis to discover how blood vessel growth could be prevented or accelerated effectively.

He has examined the birth and origin of endothelial cells, which form the thin layer that lines the interior surface of blood vessels. Endothelial cells are necessary for new blood vessel growth. Where do these highly diversified cells come from? Can their production be prevented or increased?

For a long time, it was assumed that new cells in the blood vessel walls of an adult originate in the bone marrow. In an article published in the PNAS journal in 2008, Salven's research team showed that such stem cells were not found in bone marrow.

Now Salven is ready to reveal where these mysterious stem cells originate.

"We succeeded in isolating endothelial cells with a high rate of division in the blood vessel walls of mice. We found these same cells in human blood vessels and blood vessels growing in malignant tumours in humans. These cells are known as vascular endothelial stem cells, abbreviated as VESC. In a cell culture, one such cell is able to produce tens of millions of new blood vessel wall cells," Salven said.

See the article here:
New blood-vessel-generating cells with therapeutic potential discovered

ScienceDaily (Oct. 16, 2012) Researchers at the University of Helsinki, Finland, believe they have discovered stem cells that play a decisive role in new blood vessel growth. If researchers learn to isolate and efficiently produce these stem cells found in blood vessel walls, the cells offer new opportunities in the treatment of cardiovascular diseases, cancer and many other diseases.

The study will be published Oct. 16, 2012 in the online journal PLOS Biology.

The growth of new blood vessels, also known as angiogenesis, is needed in adults when repairing damaged tissue or organs. Unfortunately, malignant tumours are also capable of growing new blood vessels to receive oxygen and nutrients. In other words, the treatment of diseases would benefit from two types of methods: ones that help launch the process of angiogenesis and ones that make it possible to prevent the process. Medications that prevent the growth of new blood vessels have already been introduced, but their effectiveness and long-term efficacy leave much to be desired.

For more than a decade, Adjunct Professor Petri Salvn from the University of Helsinki has studied the mechanisms of angiogenesis to discover how blood vessel growth could be prevented or accelerated effectively. He has examined the birth and origin of endothelial cells, which form the thin layer that lines the interior surface of blood vessels. Endothelial cells are necessary for new blood vessel growth. Where do these highly diversified cells come from? Can their production be prevented or increased?

For a long time, it was assumed that new cells in the blood vessel walls of an adult originate in the bone marrow. In an article published in the Proceedings of the National Academy of Sciences (PNAS) in 2008, Salvn's research team showed that such stem cells were not found in bone marrow.

Now Salvn is ready to reveal where these mysterious stem cells originate. His team's new study will be published in the PLOS Biology journal on 16 October 2012.

"We succeeded in isolating endothelial cells with a high rate of division in the blood vessel walls of mice. We found these same cells in human blood vessels and blood vessels growing in malignant tumours in humans. These cells are known as vascular endothelial stem cells, abbreviated as VESC. In a cell culture, one such cell is able to produce tens of millions of new blood vessel wall cells," Salvn explains.

"Our study shows that these important stem cells can be found as single cells among ordinary endothelial cells in blood vessel walls. When the process of angiogenesis is launched, these cells begin to produce new blood vessel wall cells."

The effects of new endothelial stem cells have also been tested in mice. The results show that the growth of new blood vessels weakens and the growth of malignant tumours slows if the amount of these cells in the organism is below normal. Correspondingly, a high number of new blood vessels quickly emerge where new stem cells are implanted.

Identifying stem cells among other blood vessel wall cells is challenging and time-consuming. Salvn and his team managed to identify a few molecular surface structures that make it easier to trace these stem cells. However, the efficiency of the identification process needs to be enhanced.

See the original post here:
New blood-vessel-generating cell with therapeutic potential discovered

ScienceDaily (Oct. 15, 2012) Georgia Health Sciences University researchers have developed a mouse that errs on the side of making bone rather than fat, which could eventually lead to better drugs to treat inflammatory diseases such as rheumatoid arthritis.

Drugs commonly used to treat those types of conditions -- called glucocorticoids -- work by turning down the body's anti-inflammatory response, but simultaneously turn on other pathways that lead to bone loss. The result can lead to osteoporosis and an accumulation of marrow fat, says Dr. Xingming Shi, bone biologist at the GHSU Institute of Molecular Medicine and Genetics.

The key to the body developing bone instead of fat, a small protein called GILZ, was shown in cell cultures in 2008. Now, with work by GHSU Graduate Student Guodong Pan, the work has been replicated in an animal model. Pan received the American Society for Bone and Mineral Research's Young Investigator Award for his work at the society's annual meeting Oct. 12-15 in Minneapolis.

Bone and marrow fat come from the same biological precursor -- mesynchymal stem cells. "The pathways for bone and fat have a reciprocal relationship, so we needed to find the key that disrupts the fat production pathway, which would then instead encourage bone growth," Shi says.

GILZ, Shi and Pan say, was already a known mediator of the anti-inflammatory response of glucocorticoids, and the protein also mediates bone production. Shi's early research had shown that glucocorticoids enhance bone formation in the lab because of a short "burst" of GILZ.

The protein works by inhibiting the way cells regulate fat production and turn on fat-producing genes, Shi says. "When you permanently express GILZ, the fat pathway is suppressed, so the body chooses to produce bone instead."

"We found that when we overexpressed the protein in these mice, it increased bone formation," Pan added. "This supports our original hypothesis that GILZ mediates the body's response to glucocorticoids and encourages bone growth." In fact, the genetically modified mice showed a significant increase in bone mineral density and bone volume as well, he found.

"That means GILZ is a potential new anti-inflammatory drug candidate that could spare people from the harmful effects associated with glucocorticoid therapy," Pan said

Long-term goals, Shi said, are developing the GILZ-like pill that is anti-inflammatory and protects or even increases bone production.

Share this story on Facebook, Twitter, and Google:

Here is the original post:
Protein could be key for drugs that promote bone growth

Miami, FL (PRWEB) October 15, 2012

Leveraging more than a decade of experience in the biotech industry and a founding member of GeneCell International, Jose Cirino, Director of Operations, is an industry expert for expanding awareness in the field of adult stem cells worldwide. Cirino plays a pivotal role in GeneCell Internationals success, managing all operational aspects of a company thats at the forefront of the biotech industry. While providing leadership and direction for the company, he is responsible for all strategic planning to help advance GeneCells mission and objectives, as well as the expansion of product, service and development at the national and international levels. Currently, Cirino is not only working on the expansion and awareness of cord blood services, but on the implementation of other adult stem cells sources, such as umbilical cord tissue, dental pulp, and adipose (fat) tissue into other countries. He has presentation talks in the advantage of adult cord blood banking to health and biotech industry organizations, conferences and small group meetings (both English and Spanish). Cirino was a key player in the expansion of GeneCell International into Miami, Florida, as the first and only stem cell laboratory of its kind in the South Floridian market and the gateway to international countries.

Through his field of work, Cirinos aspiration and passion is being able to assist individuals in potentially saving their life when a debilitating immune deficiency or disorder arises. Though, Cirino continuously asks himself, Why isn't everyone banking these cells?

His best assumption is that people are not informed about stem cell banking and what is most disheartening, some have never even heard of it. Most people are not aware they have stem cells in their body. Others believe that stem cells only come from only human embryos since this is whats mainly discussed in politics and the news today. May this be the reason they are choosing to have no part in it and ignore it? If so, this is not the case, these cells are found in adults and there are not controversial, moral, ethical or have any political issues surrounding them. The amazing thing about these cells, aside from their potential to treat a variety of different diseases, is that for the most part they can be harvested from the individual through relatively minimally invasive procedures and can be cryogenically frozen (at a temperature of -321 F (-196 C)) and stored for decades until a disease manifests itself or the needed for cell-based therapies arises," said Cirino.

Due to this lack of awareness, there is a massive shortage of stem cell units stored for future treatments. This shortage, or lack of availability, is mostly affecting patients of African, Asian, Hispanic and Native American Indian descent. I, being a minority member of this group, am very concerned by this shortage. Since patients who need a transplant are more likely to find a match within their own genetic background, Cirino adds it is important that the pool of donors reflects the overall community.

A persons blood stem cell type is inherited, which means a patient is more likely to find a matched donor from within their own ethnic group, more than half of cord blood donations and privately banked cord blood in the United States are from Caucasians while minorities remain underrepresented, significantly. By increasing awareness of the advantages of cord blood among minorities, there is a potential for increased access to therapies for more people.

Umbilical cord blood preservation is a process by which blood is collected from the umbilical cord of a newborn baby and is stored cryogenically in a specially-designated bank. According to the National Marrow Donor Program, cord blood contains cells that can be transfused to a patient to treat various diseases, including lymphoma and leukemia. Currently, there are approximately 80 treatable diseases and the list of illnesses continues to grow. Cord blood is rich in stem cells and because certain immune cells found in the cord blood are not mature, there is less risk for the recipients immune system to reject these cells. Cord blood can be used to treat the child from whom the blood was collected as well as some first-degree relatives who are a close genetic match, such as immediate family members. Additionally, patients can get the treatment in about three weeks - as opposed to six to eight for bone marrow from an adult donor.

Prior to founding GeneCell, Cirino served as the President of the International Division to a cord blood laboratory in Boston, Massachusetts, where he was responsible for identifying, evaluating and selecting international representatives for affiliate programs to expand the services internationally. In doing so, he coordinated laboratory development protocol license agreements and implemented these programs throughout various international countries. After the expansion into other countries, Cirino would manage the company owned offices as well as provide support to the affiliate offices, from Mexico and South America, to the UK and the Middle East. He also represented the company at international health and biotech industry conferences, implemented new sales tools and processes for all international divisions of the company, and oversaw all accounting tasks as a method of monitoring its sales projections. Cirino joined the company as the Accounting Manager, where he was responsible for all aspects of U.S. and international accounting functions. He is a seasoned accounting professional, holding various accounting positions within large companies such as Sir Speedy Printing Centers of Boston and Harvard Institute for International Development. He has served as a member within various industry organizations including the International Cord Blood Society, and New England Fertility Society, as well as participated in the International Federation of Gynecology and Obstetrics (FIGO), The Mexican Federation of Ultrasounds, The World Cord Blood Congress, and Stem Cells USA-Regenerative Medicine conferences.

In addition to cord blood, Cirinos implementation projects of other adult stem cells sources, in the U.S. and other countries, include Cord Tissue Segment, Dental Pulp and Adipose Tissue:

About Cord Tissue Segment - A gelatinous substance, which functions as the primary connective tissue of the umbilical cord and is referred to as Whartons Jelly. This segment contains an important amount of Mesenchymal stem cells. These cells are an excellent candidate for regenerative medicine and tissue engineering applications. Mesenchymal stem cells have shown great promise in the potential treatment of diseases such as heart attack, Parkinsons disease, Alzheimers disease, type I diabetes, assist in bone and dental regeneration and expedite wound healing. In the past, the umbilical cord has been viewed as medical waste and discarded, resulting in the loss of this potential life-saving resource. By storing the stem cells extracted from your umbilical cord tissue segment along with your babys cord blood, youll have access to a wider variety of stem cells as new scientific discoveries are made.

Read the original:
Director of Operations for GeneCell International, Jose Cirino, Accentuates the Importance Surrounding the Minority ...

ScienceDaily (Oct. 15, 2012) Georgia Health Sciences University researchers have developed a mouse that errs on the side of making bone rather than fat, which could eventually lead to better drugs to treat inflammatory diseases such as rheumatoid arthritis.

Drugs commonly used to treat those types of conditions -- called glucocorticoids -- work by turning down the body's anti-inflammatory response, but simultaneously turn on other pathways that lead to bone loss. The result can lead to osteoporosis and an accumulation of marrow fat, says Dr. Xingming Shi, bone biologist at the GHSU Institute of Molecular Medicine and Genetics.

The key to the body developing bone instead of fat, a small protein called GILZ, was shown in cell cultures in 2008. Now, with work by GHSU Graduate Student Guodong Pan, the work has been replicated in an animal model. Pan received the American Society for Bone and Mineral Research's Young Investigator Award for his work at the society's annual meeting Oct. 12-15 in Minneapolis.

Bone and marrow fat come from the same biological precursor -- mesynchymal stem cells. "The pathways for bone and fat have a reciprocal relationship, so we needed to find the key that disrupts the fat production pathway, which would then instead encourage bone growth," Shi says.

GILZ, Shi and Pan say, was already a known mediator of the anti-inflammatory response of glucocorticoids, and the protein also mediates bone production. Shi's early research had shown that glucocorticoids enhance bone formation in the lab because of a short "burst" of GILZ.

The protein works by inhibiting the way cells regulate fat production and turn on fat-producing genes, Shi says. "When you permanently express GILZ, the fat pathway is suppressed, so the body chooses to produce bone instead."

"We found that when we overexpressed the protein in these mice, it increased bone formation," Pan added. "This supports our original hypothesis that GILZ mediates the body's response to glucocorticoids and encourages bone growth." In fact, the genetically modified mice showed a significant increase in bone mineral density and bone volume as well, he found.

"That means GILZ is a potential new anti-inflammatory drug candidate that could spare people from the harmful effects associated with glucocorticoid therapy," Pan said

Long-term goals, Shi said, are developing the GILZ-like pill that is anti-inflammatory and protects or even increases bone production.

Share this story on Facebook, Twitter, and Google:

See more here:
Protein could be key for drugs that promote bone growth

METRO VANCOUVER -- It started with a routine blood test after a bout of pneumonia.

But since finding two rare bone marrow conditions, the family of 11-year-old Jonathan Barnes has been campaigning to shore up the list of potential marrow donors, and to keep local blood banks stocked.

Without finding a bone marrow donor who will match Jonathan's criteria, the Anmore youngster will likely end up with leukemia. Despite the frightening prospect, Jonathan and his family are meeting the challenge with poise.

"He knows he has a condition called myelodysplasia. He knows that he needs to have a bone marrow transplant," said Mariam Barnes, Jonathan's mother.

"He knows he will get cancer if he doesn't have the transplant. But in the way that children are always so wonderfully unique, he's not fazed by that."

While finding an exact match is extremely difficult, getting on the donor list is easier than most people might think, Barnes said.

"A lot of people don't do it because they think it's involving needles but the beginning step is just a mouth swab. It comes to you in the post and you post it back, and they put you on the register," she said.

"What we didn't know and what I don't think many people know, is that they're desperately short of young male donors . There's 19 million people on the transplant register across the world, but only 10 per cent of those are the groups that they need - ethnically diverse young men."

It would be easier to find a match for the family if they could use donated stem cells from umbilical chords, but that procedure won't be available in Canada until next year and the Barnes don't have that much time, she said.

"We're just praying and hoping that someone, somewhere in the world, will put forward a match that will fit with Jonathan."

More:
Anmore boy needs bone marrow transplant

ScienceDaily (Oct. 11, 2012) Early results of a Phase II intra-arterial stem cell trial for ischemic stroke showed no adverse events associated with the first 10 patients, allowing investigators to expand the study to a targeted total of 100 patients.

The results were presented October 11 by Sean Savitz, M.D., professor of neurology and director of the Stroke Program at The University of Texas Health Science Center at Houston (UTHealth), at the 8th World Stroke Congress in Brasilia, Brazil.

The trial is the only randomized, double-blind, placebo-controlled intra-arterial clinical trial in the world for ischemic stroke. It is studying the safety and efficacy of a regenerative therapy developed by Aldagen Inc., a wholly-owned subsidiary of Cytomedix, Inc., that uses a patient's own bone marrow stem cells, which can be administered between 13 and 19 days post-stroke.

The therapy, called ALD-401, consists of stem cells that are identified using Aldagen's proprietary technology to isolate cells that express high levels of an enzyme that serves as a marker of stem cells. Pre-clinical studies found that these cells enhance recovery after stroke in mice. The cells are administered into the carotid artery. Patients are followed for 12 months to monitor safety and to assess mental and physical function.

"We have been approved by the Data Safety Monitoring Board (DSMB) to move the study into the next phase, which will allow us to expand the number of sites in order to complete enrollment," said Savitz, senior investigator for the multi-center study. As per the protocol for the trial, the Food and Drug Administration required a review by the DSMB prior to advancing to the next phase.

Preclinical research, including research at the UTHealth Medical School, has suggested that stem cells can promote the repair of the brain after an ischemic stroke, which is caused by a blood clot in the brain. Stroke is a leading cause of disability and the fourth-leading cause of death in the United States, according to 2008 statistics reported by the Centers for Disease Control and Prevention.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by University of Texas Health Science Center at Houston.

View original post here:
Safety results of intra-arterial stem cell clinical trial for stroke presented

ScienceDaily (Oct. 11, 2012) Early results of a Phase II intra-arterial stem cell trial for ischemic stroke showed no adverse events associated with the first 10 patients, allowing investigators to expand the study to a targeted total of 100 patients.

The results were presented October 11 by Sean Savitz, M.D., professor of neurology and director of the Stroke Program at The University of Texas Health Science Center at Houston (UTHealth), at the 8th World Stroke Congress in Brasilia, Brazil.

The trial is the only randomized, double-blind, placebo-controlled intra-arterial clinical trial in the world for ischemic stroke. It is studying the safety and efficacy of a regenerative therapy developed by Aldagen Inc., a wholly-owned subsidiary of Cytomedix, Inc., that uses a patient's own bone marrow stem cells, which can be administered between 13 and 19 days post-stroke.

The therapy, called ALD-401, consists of stem cells that are identified using Aldagen's proprietary technology to isolate cells that express high levels of an enzyme that serves as a marker of stem cells. Pre-clinical studies found that these cells enhance recovery after stroke in mice. The cells are administered into the carotid artery. Patients are followed for 12 months to monitor safety and to assess mental and physical function.

"We have been approved by the Data Safety Monitoring Board (DSMB) to move the study into the next phase, which will allow us to expand the number of sites in order to complete enrollment," said Savitz, senior investigator for the multi-center study. As per the protocol for the trial, the Food and Drug Administration required a review by the DSMB prior to advancing to the next phase.

Preclinical research, including research at the UTHealth Medical School, has suggested that stem cells can promote the repair of the brain after an ischemic stroke, which is caused by a blood clot in the brain. Stroke is a leading cause of disability and the fourth-leading cause of death in the United States, according to 2008 statistics reported by the Centers for Disease Control and Prevention.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by University of Texas Health Science Center at Houston.

Here is the original post:
Safety results of intra-arterial stem cell clinical trial for stroke presented

ScienceDaily (Oct. 11, 2012) Researchers at Dana-Farber Cancer Institute have developed a novel method for determining how ready acute myeloid leukemia (AML) cells are to die, a discovery that may help cancer specialists to choose treatments option more effectively for their patients who have AML.

In a study published in the Oct. 12 issue of the journal Cell, the researchers report that their findings may lead to improved tests to predict which patients successfully treated for AML can continue in remission with standard chemotherapy alone, and which patients are likely to relapse despite additional treatment, but might benefit from a bone marrow transplant.

Anthony Letai, MD, PhD, senior author of the paper, said the study's results also help to explain the "therapeutic index" of AML chemo drugs: That is, how a patient's normal blood-forming stem cells can survive chemotherapy doses that kill the leukemia cells. Unlike current predictive tools, the new method determines the degree to which an individual patient's AML cells are "primed to die" by apoptosis, or programmed cell death. Chemotherapy is more effective when the cancer cells are well along the path to self-destruction, while patients with less-primed leukemia cells are more likely to suffer fatal relapse without a bone marrow transplant, said the researchers.

"Our data suggest that applying our assay in addition to conventional indicators yields a much better predictive tool," said Letai. "We plan to confirm this in independent experiments, and then test its performance prospectively in clinical trials to see if we can use it to do a better job of assigning individualized therapy in AML."

According to the American Cancer Society, an estimated 13,780 cases of AML will be diagnosed in the United States this year, and more than 10,000 people are expected to die from AML, making it the most lethal form of leukemia in the U.S.

Currently, clinicians try to predict an AML patient's outcome by assessing the cancer cells' pathological features and whether the cells contain certain mutations that suggest a poorer response. But these indicators do not provide a biological explanation for patients' differing responses to treatment, noted Letai.

The method described in the new study takes a different approach, first described by Letai in 2011 paper. It employs a technique called "BH3 profiling" to measure the readiness of mitochondria -- tiny organelles within the cell -- to unleash chemical compounds that cause the cell to destroy itself. The self-destruction process, called apoptosis, is triggered by "death molecules," whose mission is to eliminate unneeded or dangerously damaged cells from the body. The study's authors called this readiness for apoptotic self-destruction "mitochondrial priming."

BH3 profiling involves exposing cancer cells to BH3 molecules, which mimic the protein death signals in the body. If the cancer cells' mitochondria membrane is rapidly and easily disrupted, then the cells are considered to be highly primed for death. If the mitochondria strongly resist the disruption, the leukemia cells are further from self-destruction and less likely to respond to chemotherapy.

Applying the method to stored AML patient samples, "We found that mitochondrial priming measured by BH3 profiling was a determinant of initial response to induction [initial] chemotherapy, relapse following remission, and requirement for allogeneic bone marrow transplantation," the authors wrote.

Moreover, knowing whether a patient is likely to have a complete response to chemotherapy would be also very useful in personalizing chemotherapy decisions even when bone marrow transplant is not a consideration. "In elderly patients with AML, chemotherapy can be very toxic with an increased risk of fatal complications," said Letai. "You don't want to give chemotherapy unless you know whether it will benefit. Now we can predict who will benefit from it and who won't -- and should receive an alternative treatment."

Follow this link:
New tool determines leukemia cells' 'readiness to die,' may guide clinical care

Robin Roberts has returned home from the hospital, following a bone marrow transplant she received with stem cells from her sister last month.

"There's no place like home. After 30 days in the hospital I'm home," Roberts Tweeted on October 11. "Praise God from whom all blessings flow. Thank YOU and bless YOU."

The 51-year-old "Good Morning America" anchor was being treated for myelodysplastic syndrome (MDS), a rare blood and bone marrow disorder. Roberts revealed her ailment in June, saying it was caused in part by treatments she had undergone for breast cancer five years ago. Her older sister, Sally-Ann, was her bone marrow donor.

Check out 9 facts about Robin Roberts, her MDS and bone marrow transplant.

Roberts went on medical leave a day early than she had initially planned in late August in order to visit her ailing mother, Lucimarian Tolliver Roberts. Lucimarian died on August 30 at the age of 88 and Robin Roberts made it back just in time to see her mother.

In the recent blog post, Roberts detailed her difficulties with chemotherapy and how her co-workers' visit helped lift her spirits.

"Today is what I like to call 'Thankful Thursday, aka Friday Eve,'" Roberts wrote in a post on October 4. "I have been in the hospital 25 days now. My bone marrow transplant took place exactly two weeks ago. The only numbers that matter are my blood counts and they are... GREAT! My sister Sally-Ann's stem cells apparently feel right at home in my body -- an answer to so many prayers."

"My doctors and rock star nurses are very pleased with my progress and I could not be more thankful for the excellent care I am receiving," she added. "I have had some extremely painful days and it's still difficult for me to eat because of all the chemo."

Roberts also mentioned a visit she had with fellow "Good Morning America" co-workers Josh Elliott and Sam Champion, which can be seen in the photo above, as well as an upcoming visit from a childhood pastor.

"I continue to learn so much on this journey, especially when it comes to true friendship and love. My friends near and far -- like Sam and Josh who came to visit yesterday -- have been lifting my spirits," Roberts wrote. "My childhood pastor (who delivered Momma's eulogy) is coming from down South to see me tomorrow. I am hopeful that I MAY be well enough to continue my recovery at home next week and my sisters plan to come back to NYC for that milestone in my journey."

Continue reading here:
Robin Roberts returns home from hospital following bone marrow transplant